Lbp Am Sa Buys 30,837 Shares of Thermo Fisher Scientific Inc. $TMO

Lbp Am Sa grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.4% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 261,038 shares of the medical research company’s stock after acquiring an additional 30,837 shares during the period. Thermo Fisher Scientific accounts for about 1.5% of Lbp Am Sa’s investment portfolio, making the stock its 12th biggest holding. Lbp Am Sa’s holdings in Thermo Fisher Scientific were worth $105,840,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. Liberty Capital Management Inc. raised its stake in Thermo Fisher Scientific by 0.3% in the second quarter. Liberty Capital Management Inc. now owns 16,592 shares of the medical research company’s stock worth $6,727,000 after buying an additional 46 shares in the last quarter. PGGM Investments increased its position in shares of Thermo Fisher Scientific by 106.4% during the second quarter. PGGM Investments now owns 391,920 shares of the medical research company’s stock worth $158,908,000 after purchasing an additional 202,045 shares in the last quarter. Broadway Wealth Solutions Inc. increased its position in shares of Thermo Fisher Scientific by 23.2% during the second quarter. Broadway Wealth Solutions Inc. now owns 680 shares of the medical research company’s stock worth $276,000 after purchasing an additional 128 shares in the last quarter. Westhampton Capital LLC increased its position in shares of Thermo Fisher Scientific by 7.5% during the second quarter. Westhampton Capital LLC now owns 2,413 shares of the medical research company’s stock worth $978,000 after purchasing an additional 168 shares in the last quarter. Finally, Parkside Investments LLC grew its holdings in shares of Thermo Fisher Scientific by 15.7% during the second quarter. Parkside Investments LLC now owns 16,808 shares of the medical research company’s stock valued at $6,815,000 after buying an additional 2,280 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on TMO. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 24th. Robert W. Baird upped their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Evercore ISI cut their price target on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Finally, HSBC reiterated a “hold” rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Fifteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $583.53.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $484.70 on Wednesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The stock has a market capitalization of $183.03 billion, a P/E ratio of 28.03, a PEG ratio of 2.51 and a beta of 0.75. The company has a 50 day moving average price of $478.98 and a 200 day moving average price of $446.98. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $620.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts’ expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm’s revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $56,937,881. This represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 in the last ninety days. 0.33% of the stock is owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.